Hemophilia B, Severe
Showing 1 - 25 of >10,000
Hemophilia B Without Inhibitor Trial (Low dose KL001, Middle dose KL001, High dose KL001)
Not yet recruiting
- Hemophilia B Without Inhibitor
- Low dose KL001
- +2 more
- (no location specified)
Nov 5, 2023
Hemophilia B Without Inhibitor Trial (Low dose KL001, Middle dose KL001, High dose KL001)
Not yet recruiting
- Hemophilia B Without Inhibitor
- Low dose KL001
- +2 more
- (no location specified)
Nov 5, 2023
Hemophilia B Trial (CSL222 (AAV5-hFIXco-Padua))
Not yet recruiting
- Hemophilia B
- CSL222 (AAV5-hFIXco-Padua)
- (no location specified)
Aug 14, 2023
Hemophilia B Trial in Beijing (Sodium valproate extended-release tablets)
Recruiting
- Hemophilia B
- Sodium valproate extended-release tablets
-
Beijing, ChinaPLA General Hospital
Jun 17, 2023
Hemophilia A, Hemophilia B Trial in Korea, Republic of, South Africa, Taiwan (marstacimab)
Recruiting
- Hemophilia A
- Hemophilia B
-
Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of
- +3 more
Jan 18, 2023
Severe Hemophilia Non-Interventional Study
Not yet recruiting
- Hemophilia A
- Hemophilia B
- No Intervention
-
Rzeszów, Podkarpackie, Poland
- +2 more
Dec 8, 2022
Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B
Active, not recruiting
- Hemophilia B
- AAV5-hFIX
-
Berlin, Germany
- +5 more
Jan 17, 2023
Reliability and Validity of the Turkish Version of the PedHAL
Not yet recruiting
- Hemophilia
- +2 more
-
Gaziantep, Şahinbey, TurkeyHasan Kalyoncu University
Jun 2, 2023
In Vitro Correction of Thrombin Generation by Concizumab for
Recruiting
- Hemophilia
- thrombin generation measurement
-
Saint-Etienne, FranceCHU Saint-Etienne
Dec 13, 2022
Hemophilia Trial in Orange (Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate
Recruiting
- Hemophilia
- Fitusiran
- +2 more
-
Orange, CaliforniaCenter for Inherited Blood Disorders (CIBD)-Site Number:8400012
Feb 2, 2023
Hemophilia Trial in Yongin-si (MG1113)
Not yet recruiting
- Hemophilia
- MG1113
-
Yongin-si, Gyeonggi-do, Korea, Republic ofGC Biopharma Corp.
Aug 9, 2022
Hemophilia Trial in Tianjin (KN057 dose?, KN057 dose ?, KN057 dose ?)
Recruiting
- Hemophilia
- KN057 doseⅠ
- +2 more
-
Tianjin, Tianjin, China
- +1 more
Jul 20, 2022
Hemophilia A, Hemophilia B Trial in Worldwide (Fitusiran (SAR439774))
Active, not recruiting
- Hemophilia A
- Hemophilia B
- Fitusiran (SAR439774)
-
Ann Arbor, Michigan
- +11 more
Aug 4, 2022
Hemophilia B Trial in Washington (SB-FIX)
Terminated
- Hemophilia B
- SB-FIX
-
Washington, District of ColumbiaGeorgetown University Medical Center
Mar 8, 2022
DTX101 (AAVrh10FIX) in Moderate/Severe to Severe Hemophilia B
Completed
- Hemophilia B
-
Little Rock, Arkansas
- +4 more
Jan 4, 2022
Hemophilia A, Hemophilia B Trial in Tbilisi, Chisinau, Merthyr Tydfil (SerpinPC, Placebo)
Active, not recruiting
- Hemophilia A
- Hemophilia B
- SerpinPC
- Placebo
-
Tbilisi, Georgia
- +2 more
Jun 23, 2022
Liver Biopsy In Haemophilia Gene Therapy
Not yet recruiting
- Hemophilia B, Severe
- Hemophilia A, Severe
- (no location specified)
Mar 23, 2021
Hemophilia B Trial in Worldwide (AAV5-hFIXco-Padua)
Active, not recruiting
- Hemophilia B
- AAV5-hFIXco-Padua
- Factor IX (FIX)
-
Phoenix, Arizona
- +32 more
Sep 26, 2022
Severe Hemophilia A, Moderate Hemophilia A Trial in Worldwide (Emicizumab)
Recruiting
- Severe Hemophilia A
- Moderate Hemophilia A
-
Los Angeles, California
- +10 more
Aug 12, 2022
Hemophilia B Trial in United States (AAV5-hFIXco-Padua (AMT-061))
Active, not recruiting
- Hemophilia B
- AAV5-hFIXco-Padua (AMT-061)
-
Los Angeles, California
- +3 more
May 17, 2022